Who
Laura A. Williams
Chief Patient Officer
Company insider
Files Form 4 as: Chief Patient Officer, Ardelyx; Director, Enliven Therapeutics.
In numbers
- Trades disclosed
- 75
- Buys
- 1
- Sells
- 24
- Bought
- $1,860
- Sold
- $4.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 Jun 2021
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $13K3,486 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K3,089 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $9,3722,430 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $6,6881,734 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $13K3,486 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K3,089 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $9,3802,430 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $6,6931,734 at $3.86 | filing |
| 18 Jun 2026filed 22 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code M | $31K31,000 at $0.99 | filing |
| 18 Jun 2026filed 22 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $490K81,898 at $5.99 | filing |
| 18 Jun 2026filed 22 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code M | $31K31,000 at $0.99 | filing |
| 18 Jun 2026filed 22 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $491K81,898 at $5.99 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $9,4201,503 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $14K2,157 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K1,911 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $8,8871,418 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $9,4241,503 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $14K2,157 at $6.27 | filing |
News
Pomerantz LLP Issues Important Reminder to Investors in Ardelyx, Inc. ...ARDX · pr-inside.com · 25 Oct 2026Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersARDX · manilatimes.net · 23 Oct 2026November 16, 2026 Deadline: Join Class Action Lawsuit Against Ardelyx, ...ARDX · pr-inside.com · 20 Oct 2026
0 headlines in the last 90 days name Laura A. Williams; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.